ARIBIO Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.aribio.com
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AriBio Co., Ltd.
- Target Recruit Count
- 1150
- Registration Number
- NCT05531526
- Locations
- 🇺🇸
Kingfisher Cooperative, Spokane, Washington, United States
🇺🇸Vaught Neurological Services, PLLC, Crab Orchard, West Virginia, United States
🇺🇸Medical College of Wisconsin, Wauwatosa, Wisconsin, United States
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- AriBio Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT03625622
- Locations
- 🇺🇸
Advanced Clinical Research, Meridian, Idaho, United States
🇺🇸Meridien Research - Spring Hill, Spring Hill, Florida, United States
🇺🇸IMIC, Inc, Palmetto Bay, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath